12 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>European</strong> <strong>Hematology</strong> Association Dodds, A., 0578, 1445 Dodero, A., 0501, 0724, 1039 Doerrie, J., 0185 Dogan, Y., 0240 Dogan, Z.O., 1376 Doglioni, C., 0291 Dognini, G.P., 0291, 0715 Döhner, K., 0398, 0872, 0889, 0890, 0899, Döhner, H., 0010, 0099, 0108, 0118, 0189, 0398, 0410, 0417, 0694, 0872, 0889, 0890, 0899, 0909, 0925, 0930 Dojcinov, S., 1001 Dokou, H., 1309 Dolcetti, R., 0291 Dolezel, P., 1185 Dombret, H., 0048, 0055, 0060, 0222, 0315, 0383, 0397, 0427, 0474, 0859, 0923 Domingo, A., 1137 Dominguez, B., 1340 Donadel-Claeyssens, S., 1149 Donato, C., 1183 D’On<strong>of</strong>rio, M., 0279, 0812, 0847, 1083, 1138, 1329, 1401, 1482, 1526, Dore, A.I.D., 0488 Doré, E., 1366 Dorliac-Llacer, P.E., 1233 Doros, G., 0725 Dorotea, L.D., 0335 Døsen, G., 0003, 0986 Dossena, B., 0418 Doubek, M., 0098, 0105, 0114, 0451, 1056, 1110, 1537 Douglas, W., 1042 Dourado, M., 1131 Douskou, M., 0801 Dova, L., 1198, 1309 Downing, J., 0891 Doyen, C., 0465 Doz, F., 0503 Dozin, B., 0468 Drabko, K., 1368 Drach, J., 0405, 0446, 0698, 0864, 1188 Dragani, A., 1284 Draghila, L., 1423, 1493 Dragosky, M., 0703, 1422 Draisci, M.G., 0644 Drakos, E., 0290 Drandi, D., 0883 Dreger, P., 0118, 0297, 0298 Drera, M., 0633 Dresse, M.F., 0376 Drexler, C., 0757 Drexler, H., 0053, 0132, 0151, 0167, 0243, 0283 Dreyfus, F., 0040, 0222, 0231, 0323, 0427, 0428, 0430, Drize, N.J., 0074, 0970, 1358 Droll, D., 0462 Droubi, N., 1106 Druker, B., 0357, 0862 Drummond, W., 1042 Drury, S., 0779 Dry, L., 0457 D’Sa, S., 0507 Duarte, A., 0840 Duarte, A.S.S., 0632, 1061, 1272 Duarte, M., 1384 Dubart-Kupperschmitt, A., 0430 Dubois, R., 0602, 1049 j | haematologica/<strong>the</strong> hematology journal | 2007; 92(s1) Dubois, R., 0615 Dubois, V., 1485, 1486 Ducastelle, S., 0454 Duchayne, E., 1093 Duda, D., 0213, 0558 Duechler, M., 0912 Duerig, J., 0522, 0524 Dufour, C., 0076, 0438 Dugan, M., 0153 Duh, M.S., 0560 Duhamel, A., 0272 Dührsen, U., 0379, 0380, 0410, 0524 Duke, V., 0876 Dukka, S., 0087 Duletic-Nacinovic, A., 1369 Dulman, I., 0018 Dumenil, D., 0931 Dumontet, C., 1485, 1486 Duner, E., 0244 Dunkler, D., 0880 Dunlop, L., 0660 Dupont, J., 0307 Dupont, S., 0249, 0443 Dupuis, M., 0316 Duque, F., 0161 Durak, B., 1172 Durakovic, N., 0622, 0687 Duran, M.A., 1137 Duru, F., 1393 Dusse, L., 0352, 0353, 1028 Duszynska, M., 0340, 1326 Dutka, M., 0618 Dutrillaux, F., 0354, 1067 Dutt, T., 0388 Duvillier, H., 0111 Duyster, J., 0905 Dvorakova, D., 0105, 0281, 1056, 1110, 1449, 1501, 1537, Dwilewicz-Trojaczek, J., 0263, 0120 Dworzak, M., 0020 Dyachenko, O.V., 0162 Dyagil, I.S., 1019, 1122 Dybko, J., 0981 Dybowicz, J., 0120 Dyer, M., 0096 Dyla, A., 0585 Dyson, J., 1025 Dytfeld, D., 0594 Dziaczkowska, J., 0595 Dziamska, J., 1283 Dzietczenia, J., 1288, 1499 E Eapen, M., 0370 Eaves, A., 0221 Eaves, C., 0221 Ebeid, E., 0016 Ebeling, P., 0524, 1076 Eberhart, K.E., 1128 Ebetsberger, G., 0874 Ebralidze, A., 0445 Eckh<strong>of</strong>f, S.M., 0472 Eckstein, R., 0185 Eclache, V., 0467, 0887 Economopoulos, T., 0180, 0286 Economopoulou, E.C., 0286 Economou-Petersen, E., 1143 Eder, J.P., 0742 Eder, M., 0240, 0368, 0625 Eduardo, E., 1396 Effraimidou, S., 0079 Efremov, D.G., 0990 Efthymiou, A., 0628 Egeler, M., 0421 Egin, Y., 0088, 0819 Egyed, M., 0446, 1026 Ehninger, G., 0188, 0223, 0579 Ehret, S., 0898 Eichinger, S., 0355, 0882 Eick, D., 1300 Eid, K.A.B., 1181 Eid, M., 1421 Eide, C., 0436 Eide, G.E., 0309 Einsele, H., 0320 Eischer, L., 0355 Eisenbach, M., 0038 Eiwen, K., 0899 El Accaoui, R., 0795 El Ali, M., 1380 El Awady, M., 1397 El Bassiouny, A.E. I., 1478 El Hachem, M., 0452 El Hajj, H., 0145, 0310 El Sorady, M., 1334 El Weshi, A., 0950 El-Agnaf, M.R., 0938, 0348, 0678 El-Ahwany, E.G., 1478 Elalfy, M., 0808 El-Bassiouni, E.I., 1478 Elbaz, E., 1397 El-Beshlawy, A., 0808 Elbostany, E., 1142 El-Cheikh, J., 0158, 0455 Elebute, M., 0379 Elef<strong>the</strong>riou, A., 0798 Elef<strong>the</strong>riou, P., 0798 Elena, C., 0647, 0649 Elezovic, I., 0683, 1069, 1104, 1361 Elghandour, A., 1334, 1535 El-Gharib, A., 1405 El-Haddad, A., 0016 Elhamri, M., 0397 Elia, L., 0013 Elias, A.P., 0629, 0840 Elias Junior, J., 0488 Elice, F., 1350 Elie, C., 0040 Elion, J., 0842 Eliopoulos, G.D., 0064, 0327, 0437, 0962 Eliwan, H., 0800 Elkamash, M., 1514 Elkhina, E., 1460 El-Khoury, H., 1462 Elkin, G., 1097 El-Kinge, A., 1106 El-Kinge, N., 1002 Ellervik, C., 0165 Elliot, J., 0041, 0237, 0313 Ellis, L., 0153 Ellmeier, W., 0435 Elloumi, M., 1091, 1298 El-Nahass, Y., 0016 Elonen, E., 0315 Elosegui, A., 1137 El-Sabban, M., 0145, 0146, 0310, 1002, 1462 El-Saghir, N., 1106 El-Samahi, A., 1112 El-Serogy, H., 1421
El-Sharkawy, N., 0016 Elwahidi, G., 1415 El-Ziny, M., 0960 Emberger, W., 0854 Endler, G., 1112 Engelhardt, R., 1075 Enoch, D.A., 0202 Enzenh<strong>of</strong>er, K., 0164 Eom, H.S., 0720 Eom, K.S., 0939, 0941, 0961, 1407 Equeter, C., 0513 Eramishantsev, A., 0818 Erario, M., 0168 Erbas, B., 1332 Erben, P., 0356, 0534, 0545, 0568, 0861 Erber, W.N., 0894 Erbilgin, Y., 0154, 0155, 0173, 1095 Erdmann, M., 0185 Erdogan, F., 0009 Erdur, B., 0987 Erer, B., 0184, 1295 Ergand, L., 0248 Eriksson, S., 0317 Ernst, T., 0356, 0534, 0545, 0568 Ersoy, A.O., 1469 Ersvaer, E., 1347 Ertug, S., 1319 Esc<strong>of</strong>fre-Barbe, M., 0222, 0427 Escribano, L., 0070 Eser, B., 1055, 1469, 1472 Eshel, R., 0187 Eskander, G., 1514 Espérou, H., 0999 Espigado, I., 0972, 1269 Espina, V., 0888 Espinet, B., 0646 Espirito Santo, A., 0664 Esposito, E.L., 0790, 1157 Esposito, J., 1027 Esposito, M., 0113 Esposito, N., 1135 Esquibel, V., 0418 Esseltine, D.-L., 0404, 0695 Esterbauer, H., 0652, 1074 Esterni, E., 0158 Esteve, J., 0399, 0487, 0727 Estey, E., 0059 Estrov, Z., 0363 Eswedi, A.-H., 0938 Eswedi, A.S., 0678 Etienne, A., 0055 Evangelatos, N.G., 1256 Ewing, J., 0119, 0619 Exeni, R., 1183 Exeni, S., 1183 Ezpeleta, I., 1151, 1324 Ezzeddine, R., 0358 F Fabbi, M., 0517 Fabbiano, F., 0576 Fabbri, L.M., 0212 Faber, J., 0045 Fabian, P., 0702 Fabiani, E., 0635 Fabre, C., 0428, 0482 Fabris, F., 1126 Fabris, P., 0423 Fabris, S., 0116, 0697, 0973 Facchetti, F., 0285, 0633 Faccia, S., 0616, 1187, 1299, 1381 Facco, M., 0278, 1024 Facon, T., 0272, 0358, 0690, 0770 Faderl, S., 0072, 0363 Fagioli, F., 1274 Fähnrich, S., 0167 Faiz, M., 1479 Falanga, A., 0057, 0895 Falantes, J.F., 1090, 1094 Falantes Gonzalez, J., 1508 Falappa, P., 1195 Falcão, R.P., 0477, 0488, 0944 Falco, P., 0254, 0258, 0402 Falcone, A.P., 0325, 1133, 1196 Falcone, A., 0254, 0422, 0402, 0401, 1301, 1302, 1511, Falcucci, P., 0823 Falda, M., 0403 Falini, B., 0385, 0576, 0902 Fallani, S., 0991 Faltz, C., 0584 Fanale, M., 0942 Fang, R.Y., 0739 Fanin, R., 0403, 0458, 0459, 0460, 0496, 0562, 0724, 0745, 1200 Fantasia, D., 0666 Fantauzzo, A., 0193, 0693 Fantini, N.N., 0168 Faraci, M., 0588 Farhat, H., 0048 Farina, F.L., 0724 Farina, G., 0351, 0589, 0604, 1078 Farina, L., 0501 Farmaki, K., 0809, 1328 Farrag, W., 1421 Fasanaro, A., 0050 Fassas, A., 1264, 1534 Fasth, F., 0370 Fattel-Fazenda, S., 1212 Fattori, A., 1495 Faucher, C., 0158, 0455 Favarin, M.C., 0614, 1463 Favata, M., 0324 Favier, R., 0149 Favre-Bonvin, A., 0145 Fay, K., 1445 Fazio, G. F., 0877 Fechina, L., 1098, 1245, 1437 Federici, A., 0092 Federici, A.B., 0091, 0092, 0881 Federici, L., 1317, 1335 Federico, M., 0692, 0863 Federico, V., 1064 Fedorenko, D., 0504 Fegan, C., 0365 Fehse, B., 0420 Felipo, F., 0294 Feliu, E., 0293, 0372, 0461, 1199 Felman, P., 0166, 0288, 0292 Fenaux, P., 0222, 0227, 0229, 0427, 0428, 0482, 0639, 0642, 0923 Fenu, S., 0991 Feola, B., 0279, 0847, 1083, 1138, 1401 Feremans, W., 1153 Fermo, E., 0784, 0787, 1325 Fernandes, A., 0664, 1459 Fernández, A., 1046, 0174 Fernández, J., 1046 Fernández, M.N., 0839 Fernandez-Abellan, P., 0372 12 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>European</strong> <strong>Hematology</strong> Association Fernandez-Alvarez, C., 0820, 0831 Fernandez-Calvo, J., 0372, 0700 Fernández-Canal, C., 0820, 0829, 0831 Fernandez-Carreira, J.M., 0831 Fernandez-Jurado, A., 1144 Fernandez-Mosteirin, N., 0624, 0827, 0828, 1006, 1414, 1443, 1525, Fernández-Villamor, A., 0748 Ferra, C., 0461, 1199 Ferrajoli, A., 0072, 0363 Ferrant, A., 0222, 0427, 0465 Ferrante, F., 0093 Ferranti, M., 0674 Ferrara, F., 0050, 0051, 0600, 0765, 1350 Ferrara, J.L., 0160 Ferrara, M.F., 0790, 1157 Ferrara, M.G., 1425 Ferrari, A., 0212 Ferrari, L., 0336 Ferrari, M.D., 1007 Ferrarini, M., 0116, 0126, 0517, 0518 Ferreira, A., 0528 Ferreira, E., 1241 Ferreira, F., 0025, 0664, 0783, 0786, 1459 Ferreira, J., 1194 Ferrer, A., 0304 Ferrer Chavez, C., 1152 Ferreri, A., 0717, 0867 Ferreri, A.J.M., 0291, 0715 Ferrero, D., 0659 Ferretti, E., 0076 Ferri, L., 0168 Ferrini, S., 0517 Ferro, F., 0193, 0693 Ferry, C., 0216 Ferster, A., 0376 Fesce, V., 1073 Festini, G., 0116, 0126 Feuerhake, F., 1062 Feugier, P., 0115, 0407 Feuring-Buske, M., 0032 Feys, H.B., 0838 Ffrench, M., 0292, 1366 Fianchi, L., 1023 Fidalgo, T., 1205 Fiegl, M., 0648 Fielding, A.K., 0381 Fietkau, R., 0027, 0374, 0410 Figueiredo, J.F.C., 0614, 1463 Figueiredo, M.S., 0791 Figueiredo-Pontes, L.L., 0477, 0488, 0614, 1463 Filardi, N., 0677 Filatov, F.P., 0740 Filì, C., 0459, 0496, 0745, 1200, 1296 Filip, S., 1210 Filkova, H., 0136, 1383 Finashutina, Yu.P., 1015, 1016, 1362 Finazzi, G., 0245, 0601, 1127 Finizio, O., 1425 Finnegan, D., 1139 Finogenova, N., 1165, 1490 Finotto, S., 1126 Fiore, F., 0193, 0403 Fiorilli, M., 0139 Fiorini, A., 0589, 0990, 1078 Fioritoni, G., 0666 Fisac, R., 1105 Fisac-Herrero, R.M., 0680 Fischer, C., 0151 haematologica/<strong>the</strong> hematology journal | 2007; 92(s1) | k
- Page 1 and 2:
haematologica the hematology journa
- Page 3 and 4:
Information for readers, authors an
- Page 5 and 6:
EHA Executive Board E. Hellström-L
- Page 7 and 8:
Poster session I POSTER SESSION POS
- Page 9 and 10:
12 th Congress of the European Hema
- Page 11 and 12:
dasatinib. Methods. We studied Ikar
- Page 13 and 14:
Expression of the oncogene H-Ras an
- Page 15 and 16:
is the gene for the erythropoietin
- Page 17 and 18:
safety of a slow-release liposomal
- Page 19 and 20:
0029 OUTCOME OF THE TREATMENT OF AD
- Page 21 and 22:
drug-induced apoptotic response of
- Page 23 and 24:
41% in the PI3K- group (p=0.001). I
- Page 25 and 26:
Acute myeloid leukemia - Clinical I
- Page 27 and 28:
to 60 years (n=116, or 72%) receive
- Page 29 and 30:
0056 PROGNOSTIC SIGNIFICANCE OF FLT
- Page 31 and 32:
Anemia and Bone marrow failure 0061
- Page 33 and 34:
tified with the current protocol. S
- Page 35 and 36:
new cases of lead poisoning due to
- Page 37 and 38:
icance, from baseline to week 6 (p
- Page 39 and 40:
0086 THROMBELASTOGRAPHIC CHART RELI
- Page 41 and 42:
trials. The aim of this retrospecti
- Page 43 and 44:
tant function in this disease, nega
- Page 45 and 46:
ed to a favorable outcome. Bialleli
- Page 47 and 48:
stronger levels of p21 in the cell
- Page 49 and 50:
hematological centers in one countr
- Page 51 and 52:
ure 1). Conclusions. Results for re
- Page 53 and 54:
patients. After a median follow-up
- Page 55 and 56:
Cytogenetics and Molecular diagnost
- Page 57 and 58:
0135 ROUTINE DETECTION OF CYTOGENET
- Page 59 and 60:
(MMolR, defined as a BCR-ABL x 100
- Page 61 and 62:
0146 ARSENIC TRIOXIDE INDUCES ACCUM
- Page 63 and 64:
tinguish between genotypic B-cell l
- Page 65 and 66:
Genomics and proteomics 0158 PLASMA
- Page 67 and 68:
0164 EVALUATION OF MULTIPLEX LIGATI
- Page 69 and 70:
each patient’s replicate conditio
- Page 71 and 72:
0174 RELATION BETWEEN LOW PML-RARα
- Page 73 and 74:
0179 ESHAP VS GIN AS SALVAGE AND MO
- Page 75 and 76:
Immunology and gene therapy 0184 EA
- Page 77 and 78:
Cell viability was not affected by
- Page 79 and 80:
month is not relevant to chronic Gv
- Page 81 and 82:
Infection and supportive care I 020
- Page 83 and 84:
0206 POTENTIAL ROLE OF CMV IN THE O
- Page 85 and 86:
3H-thymidine uptake in cell culture
- Page 87 and 88:
0217 TUBERCULOSIS AMONG A COHORT OF
- Page 89 and 90:
0222 COMPARISON OF IWG 2006 AND IWG
- Page 91 and 92:
tem (IPSS) to h-MDS was also invest
- Page 93 and 94:
PCH97-19) were studied. Conventiona
- Page 95 and 96:
of erythroid colonies was reduced i
- Page 97 and 98:
0245 POTENT AND SELECTIVE INHIBITIO
- Page 99 and 100:
0250 INACTIVATION OF SUPPRESSOR OF
- Page 101 and 102:
Bortezomib 1.3 mg/m 2 days 1,4,8,11
- Page 103 and 104:
Response was defined according to E
- Page 105 and 106:
G-CSF can be used in neutropenic pa
- Page 107 and 108:
ence and functional activity of CD8
- Page 109 and 110:
itating tumor development, or engag
- Page 111 and 112:
phoma and SNT-13, -15 were establis
- Page 113 and 114:
usage (2/20 ie 10%) were observed.
- Page 115 and 116:
0294 MYCOSIS FUNGOIDES. IMMUNOHYSTO
- Page 117 and 118:
(range, 1-6) and 11 treatment cycle
- Page 119 and 120:
0306 RISK-ADAPTED IMMUNOCHEMOTHERAP
- Page 121 and 122:
functional activity was confirmed b
- Page 123 and 124:
No major toxicity, neither hematolo
- Page 125 and 126:
enewal potential of X-RAR-positive
- Page 127 and 128:
(50-99) respectively. Serial analys
- Page 129 and 130:
cell-interaction, adhesion and acti
- Page 131 and 132:
0340 ALTERED FIBRIN CLOT STRUCTURE
- Page 133 and 134:
Conclusions. This study demonstrate
- Page 135 and 136:
0354 FACTOR V LEIDEN HOMOZYGOUS GEN
- Page 137 and 138:
Results. From July 2005 through Mar
- Page 139 and 140:
0364 CLINICAL EFFICACY OF OXALIPLAT
- Page 141 and 142:
one marrow and peripheral blood ste
- Page 143 and 144:
ecently suggested (Boissel et al.,
- Page 145 and 146:
0378 SAFETY AND EFFICACY OF THE TER
- Page 147 and 148:
Cytogenetics and molecular diagnost
- Page 149 and 150:
0385 CYTOPLASMIC MUTATED NUCLEOPHOS
- Page 151 and 152:
0390 ELTROMBOPAG RAISES PLATELET CO
- Page 153 and 154:
factor for the achievement of CR wa
- Page 155 and 156:
The cases of RAS showed two peaks o
- Page 157 and 158:
is 85%. Seven out of the 25 relapse
- Page 159 and 160:
0409 FRACTIONATED RADIOIMMUNOTHERAP
- Page 161 and 162:
0414 COMPARATIVE ANALYSIS OF THE CO
- Page 163 and 164:
successfully managed with GM-CSF di
- Page 165 and 166:
49% for PCR positive patients (95%
- Page 167 and 168:
+8 (1 PR+1 HI) and 14/24 pts with c
- Page 169 and 170:
(e.g. bcr-abl leading to CML). CSC
- Page 171 and 172:
0438 TERC MUTATIONS ANALYSIS IN PAT
- Page 173 and 174:
observed in all mice. Analysis of l
- Page 175 and 176:
ex-vivo expansion of HUCB-derived H
- Page 177 and 178:
ic kidney disease in univariate or
- Page 179 and 180:
One hundred eleven CN AML patients,
- Page 181 and 182:
to asses intestinal epithelial dama
- Page 183 and 184:
genesis of acute myeloid leukaemia
- Page 185 and 186:
polymorphism at nucleotide 4889 of
- Page 187 and 188:
expression along with a decreased C
- Page 189 and 190:
0487 MUTATIONAL STATUS OF NUCLEOPHO
- Page 191 and 192:
previously reported, a single cours
- Page 193 and 194:
0497 SINGLE AGENT CLORETAZINE (VNP4
- Page 195 and 196:
ly received melphalan-based chemoth
- Page 197 and 198:
were similar among the 3 groups. Ho
- Page 199 and 200:
Methods. Several read-out systems w
- Page 201 and 202:
0518 SERUM AND CELLULAR EXPRESSION
- Page 203 and 204:
0523 DNA REPAIR INHIBITION IN RESTO
- Page 205 and 206:
held true when BMI-1 expression was
- Page 207 and 208:
Ph + cells in the bone marrow). We
- Page 209 and 210:
derivative chromosome (4p16, 7p14,
- Page 211 and 212:
0545 STABILIZED BONE MARROW IS NOT
- Page 213 and 214:
obtained in low (Sokal) risk patien
- Page 215 and 216:
median dose intensity being 800 (21
- Page 217 and 218:
from pivotal clinical trials. Metho
- Page 219 and 220:
Cytogenetics and Molecular diagnost
- Page 221 and 222:
to set up and optimize a D-HPLC-bas
- Page 223 and 224:
0576 WESTERN BLOT IDENTIFICATION OF
- Page 225 and 226:
Basic disease was AML (n=5), ALL (n
- Page 227 and 228:
0588 EXTRACORPOREAL PHOTOPHORESIS F
- Page 229 and 230:
acquire a cytolytic capacity agains
- Page 231 and 232:
informed vignettes describing healt
- Page 233 and 234:
using CHOP-21 in the UK, pegfilgras
- Page 235 and 236:
0609 SOFT TISSUE COMPLICATIONS IN P
- Page 237 and 238:
inding lectin (MBL) gene by polymer
- Page 239 and 240:
all infection rate (p=0.12) as well
- Page 241 and 242:
Myelodysplastic syndromes II 0623 M
- Page 243 and 244:
formation (in total 28 samples). Ti
- Page 245 and 246:
sion. In addition, confocal analysi
- Page 247 and 248:
Myeloproliferative disorders - Clin
- Page 249 and 250:
open-label, multi-centre study enro
- Page 251 and 252:
iopsies after 6 and 12 months treat
- Page 253 and 254:
Myeloproliferative disorders Chroni
- Page 255 and 256:
ash, muscolar cramps, diarrhoea, he
- Page 257 and 258:
induced significant apoptosis (mean
- Page 259 and 260:
Myeloma and other monoclonal gammop
- Page 261 and 262:
the therapy of choice for POEMS is
- Page 263 and 264:
er patient does not indicate such t
- Page 265 and 266:
Myeloma and other monoclonal gammop
- Page 267 and 268:
secutive patients with MM, referred
- Page 269 and 270:
whether gene expression values may
- Page 271 and 272:
0705 THE SHIFT OF TREATMENT FOR NAS
- Page 273 and 274:
0710 CLINICO-PATHOLOGICAL FEATURES,
- Page 275 and 276:
patients presented a stage IV disea
- Page 277 and 278:
plete remission or recurrent diseas
- Page 279 and 280:
known at NHL diagnosis, were includ
- Page 281 and 282:
0731 THE IMPACT OF HIV ON NON-HODGK
- Page 283 and 284:
patients had died of their underlyi
- Page 285 and 286:
scripts and proteins most affected
- Page 287 and 288:
modulated after 24 h (37 up- and 59
- Page 289 and 290:
0753 A SUSTAINED REMISSION OF IDIOP
- Page 291 and 292:
and treatment, has rarely been syst
- Page 293 and 294:
uncontrolled massive bleeding affec
- Page 295 and 296:
Results. A total of 396 patients we
- Page 297 and 298:
C30 questionnaire, and the correspo
- Page 299 and 300:
wave length of light of reflected r
- Page 301 and 302:
0783 PREVALENCE OF MEMBRANE PROTEIN
- Page 303 and 304:
erozygous mother has a more severe
- Page 305 and 306:
0794 CARDIAC MANIFESTATIONS IN A BR
- Page 307 and 308:
0799 INEFFECTIVE ERYTHROPOIESIS IN
- Page 309 and 310:
p=0.014 and p=0.003, respectively).
- Page 311 and 312:
0809 CURRENT APPROACH TO CHELATION
- Page 313 and 314:
Thrombosis II 0814 UNSUSPECTED PULM
- Page 315 and 316:
the 97.5th percentile (5.2 U/mL) ge
- Page 317 and 318:
symptoms of DVT, 3 (7.89%) previous
- Page 319 and 320:
Transfusion medicine and vascular b
- Page 321 and 322:
tions (most bacterial, 2 malaria, 6
- Page 323 and 324:
0844 INCREASED LEUKOCYTE-PLATELET I
- Page 325 and 326:
0851 CORD BLOOD DERIVED MESENCHYMAL
- Page 327 and 328:
SIMULTANEOUS SESSION II Chronic mye
- Page 329 and 330:
0862 COMPARISON OF DASATINIB TO HIG
- Page 331 and 332:
0867 COMPREHENSIVE GERIATRIC ASSESS
- Page 333 and 334:
0872 MN1 INDUCES LEUKEMIA IN MICE A
- Page 335 and 336:
0877 PAX5/TEL TRANSDUCED PRE-BI CEL
- Page 337 and 338:
0882 CISPLATIN INDUCES THROMBIN GEN
- Page 339 and 340:
have an early manifestation of typi
- Page 341 and 342:
0892 INTEGRATION OF GENOME WIDE SNP
- Page 343 and 344:
0897 THE PHENOTYPE OF JAK2V617F MUT
- Page 345 and 346:
gest diverse sequences of NPM mutan
- Page 347 and 348:
2004 to January, 2006. At enrollmen
- Page 349 and 350:
with a p value of ≥ 0.10. Sets of
- Page 351 and 352:
BRIC 126 and 4N1K) in cells lacking
- Page 353 and 354:
sclerosis[NS] and 12 Mixed cellular
- Page 355 and 356:
0927 MK-0457, A NOVEL MULTIKINASE I
- Page 357 and 358:
Publication Only 0933 CLINICAL FEAT
- Page 359 and 360:
HSCT from the available Asian as we
- Page 361 and 362:
that the incidence of JAK2 mutation
- Page 363 and 364:
without type 2 diabetes. Methods. T
- Page 365 and 366:
pts (38.8%) that were isolated (abs
- Page 367 and 368:
y using the Miltenyi CD34 isolation
- Page 369 and 370:
0969 COMPARISON OF CD25 IMMUNOHISTO
- Page 371 and 372:
cytes was 24 days (range 8-32 days)
- Page 373 and 374:
a cytogenetic hallmark for M4/M5 su
- Page 375 and 376:
normal human BM B progenitor cells
- Page 377 and 378:
0994 INCIDENCE OF INVASIVE ASPERGIL
- Page 379 and 380:
3 of disease relapse.TRM at day+100
- Page 381 and 382:
survival of five years. This dismal
- Page 383 and 384:
1011 FLOW CYTOMETRIC DNA INDEX AND
- Page 385 and 386:
1018 THE EFFECT OF THE SUGARBAKER P
- Page 387 and 388:
1024 KIR/HLA CLASS I MISMATCHING AN
- Page 389 and 390:
ment details and thrombotic histori
- Page 391 and 392:
1036 INCIDENCE AND SPECTRUM OF INFE
- Page 393 and 394:
tinely by our stem cell lab prior t
- Page 395 and 396:
tion to a translocation t(5;14)(q35
- Page 397 and 398:
ment of CML and induces a high rate
- Page 399 and 400:
due to reactivation and/or progress
- Page 401 and 402:
1063 ABNORMAL METHYLATION STATUS OF
- Page 403 and 404:
1069 CLINICAL RELEVANCE OF REGULATO
- Page 405 and 406:
1076 SERUM LEVELS OF SOLUBLE HLA CL
- Page 407 and 408:
patient is still undergoing intensi
- Page 409 and 410:
nificant MVD differences were detec
- Page 411 and 412:
dictor of OS (p=0.004). High dose t
- Page 413 and 414:
1099 ALTERATIONS IN THE NATURAL KIL
- Page 415 and 416:
1105 CYTOGENETIC ABNORMALITIES IN 3
- Page 417 and 418:
1110 CONSTITUTIVE ACTIVATION OF STA
- Page 419 and 420:
efficacy results with a well-tolera
- Page 421 and 422:
unmutated VH genes, and high and lo
- Page 423 and 424:
Aims. Aim of this study was to pred
- Page 425 and 426:
tested across a wide range of human
- Page 427 and 428:
were incidentally diagnosed (52%).
- Page 429 and 430:
ß2GP1 may be considered as determi
- Page 431 and 432:
characterized in 198 β thalassaemi
- Page 433 and 434:
1155 PLATELET AGGREGATION IN CHILDR
- Page 435 and 436:
to-pelvic or perineal trauma. No me
- Page 437 and 438:
in age. High prevalence of LBM amon
- Page 439 and 440:
ecause some of the patients were or
- Page 441 and 442:
of the drug is crucial to allow lon
- Page 443 and 444:
egarding cost analysis of ASCT in G
- Page 445 and 446:
ID Allo-BMT, 1 family one mismatche
- Page 447 and 448:
admitted to ICU were discharged des
- Page 449 and 450:
events -Postoperative states: 9,19%
- Page 451 and 452:
efficacy and decreased atherosclero
- Page 453 and 454:
1217 INCIDENCE OF EARLY STAGE IDIOP
- Page 455 and 456:
1691GA and 1 homozygous 1691AA. The
- Page 457 and 458:
1230 ASSOCIATION OF HEPARANASE GENE
- Page 459 and 460:
posed, was: DF = (CD43%+FMC7%+CD79b
- Page 461 and 462:
treatment of acute promyelocityc le
- Page 463 and 464:
loaded group and 35 (70%) were non-
- Page 465 and 466:
mild. Fas and soluble Fas ligand le
- Page 467 and 468:
1265 POSACONAZOLE THERAPY IN REFRAC
- Page 469 and 470:
ly express the cytoplasmic (inactiv
- Page 471 and 472:
findings confirmed the significant
- Page 473 and 474:
a less favorable prognosis. Interes
- Page 475 and 476:
disease (HD), 4 patients (9%) with
- Page 477 and 478:
1295 HEMOPHAGOCYTIC LYMPHOHYSTIOCYT
- Page 479 and 480:
phamide 750 mg/m 2 on day 1, vincri
- Page 481 and 482:
nomenon is unclear. It has been sug
- Page 483 and 484:
oped mild thrombocytopenia (platele
- Page 485 and 486:
gle dose of 54mg/m 2 rituximab furt
- Page 487 and 488:
patients (pts), 36 male, with acute
- Page 489 and 490:
esulting alterations of the endothe
- Page 491 and 492:
(range 1-7) and 28,6% of patients h
- Page 493 and 494:
three decades. In vivo, Ara-C is tr
- Page 495 and 496:
statistical analysis. Results. Seve
- Page 497 and 498:
Results. Though there was no recogn
- Page 499 and 500:
2% and 19% of patients with or with
- Page 501 and 502:
were older than 65 y) which can be
- Page 503 and 504:
1376 RESVERATROL INDUCED P53 MEDIAT
- Page 505 and 506:
median time of 21 days to reach >0.
- Page 507 and 508:
ly. Conclusions. 1. Combined intens
- Page 509 and 510:
to the presence of IVS1-6 mutation
- Page 511 and 512:
fy predictive factors for these abn
- Page 513 and 514:
acute leukemia. However, we cannot
- Page 515 and 516: agents. They involve primarily the
- Page 517 and 518: voriconazole for 2 months followed
- Page 519 and 520: typed using a commercially availabl
- Page 521 and 522: low up of ABL KD mutations’ level
- Page 523 and 524: with development of BC/AP. 2. EVI-1
- Page 525 and 526: 1447 THE IMPACT OF DISPARITY IN SHO
- Page 527 and 528: three had visual field defects, two
- Page 529 and 530: acquired mutation most prone to cau
- Page 531 and 532: 1466 ROS GENERATION AND APOPTOSIS I
- Page 533 and 534: 1473 DIARRHEIC SYNDROME, A CLINICAL
- Page 535 and 536: gene fusion is an independent progn
- Page 537 and 538: 1484 EPIDEMIOLOGY AND RESPONSE TO T
- Page 539 and 540: 1492 FREQUENCY OF MEDITERRANEAN GLU
- Page 541 and 542: immune globulin was administered at
- Page 543 and 544: maintained on Imatinib 400 mg. Afte
- Page 545 and 546: Hodgkin’s disease is well known,
- Page 547 and 548: gram provided a unique chance to de
- Page 549 and 550: even when ADP-induced plt activatio
- Page 551 and 552: medullary involvement of multiple m
- Page 553 and 554: 1540 ADMINISTRATION OF G-CSF AND CH
- Page 555 and 556: 1548 QUALITY ANALYSIS OF THE MULTID
- Page 557 and 558: Index of authors A Aapro, M., 0377,
- Page 559 and 560: Bahr, J., 0148 Bai, M., 1551 Baia,
- Page 561 and 562: Bottini, P.V., 1181 Botto, B., 0408
- Page 563 and 564: Chaidos, A., 0456, 0498, 0599, 0686
- Page 565: De Keersmaecker, K., 0442, 0875 De
- Page 569 and 570: Garcia-Frade, J., 0346, 0680, 1105
- Page 571 and 572: H Haas, N., 0742 Haas, O.A., 0001,
- Page 573 and 574: Jaksic, B., 0127, 0446 Jaksic, O.,
- Page 575 and 576: Körmöczi, G., 0848 Kornblau, S.,
- Page 577 and 578: Lin, L.-I., 0030, 0484 Lin, T., 012
- Page 579 and 580: Massé, A., 0249 Massó, P., 1287,
- Page 581 and 582: Musto, P., 0254, 0401, 0422, 0569,
- Page 583 and 584: Papadavid, E., 1442 Papageorgiou, E
- Page 585 and 586: Probatova, N., 0704 Prochazka, V.,
- Page 587 and 588: Rykavicin, O., 0504 Ryningen, A., 0
- Page 589 and 590: Sirard, C., 0127, 0128 Sirigou, A.,
- Page 591 and 592: Thiebaut, A., 0454 Thieblemont, C.,
- Page 593 and 594: Vincenzi, C., 1060 Viniou, N.-A., 0
- Page 595 and 596: Zouabi, H., 0503, 0999 Zoumbos, N.C
- Page 597 and 598: 12 th Congress of the European Hema
- Page 599 and 600: 12 th Congress of the European Hema
- Page 601 and 602: 12 th Congress of the European Hema
- Page 603: 12 th Congress of the European Hema